Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

FDA Halts Enrollment on 3 Nivolumab Myeloma Trials

September 7th 2017

The FDA has placed partial clinical holds on 3 trials assessing nivolumab (Opdivo)-based combinations in patients with relapsed/refractory multiple myeloma.

Proposed Changes to 340B May Curb Hospital Abuses

September 2nd 2017

Outpatient branded drug sales in the 340B Drug Pricing Program now amount to almost 8% of the total market, well up from 5.4% in 2012.

Novartis Sets a Price of $475,000 for CAR T-Cell Therapy

August 31st 2017

Novartis’ just-approved chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel is going to be introduced on the market at a price of $475,000 for a single infusion, an amount that is within the range anticipated by oncologists.

The Value of MRD Testing in Lymphoid Malignancies

August 29th 2017

MRD Negativity in Multiple Myeloma

August 29th 2017

Reliability of MRD Testing: Sensitivity/Specificity

August 29th 2017

Varying Pertinence: MRD Testing Across Lymphomas

August 29th 2017

How to Properly Utilize MRD Testing

August 29th 2017

An Overview of Minimal Residual Disease Testing

August 29th 2017

Understanding MRD Testing in CLL

August 29th 2017

CLL: MRD Testing Platforms

August 29th 2017

MRD Timepoints in CLL

August 29th 2017

CLL: Value of MRD Testing

August 29th 2017

Goals of Therapy in CLL

August 29th 2017

Palliative Care Consultations Significantly Reduce Healthcare Utilization

August 29th 2017

End-of-life palliative care consultations can significantly reduce healthcare utilization, according to a broad-based population study published in the Journal of Oncology Practice.

Artificial Intelligence Is Still a Long Way From Understanding the Subtlety of a Texas Metaphor

August 27th 2017

It is not far-fetched to believe that, one day soon, automated systems will be able to obtain payer approval for therapies without any human involvement.

What If You Cannot Afford CAR T-Cells?

August 26th 2017

Despite all the excitement and anticipation, there is a growing anxiety among payers and providers regarding the cost of CAR T cells.

Cota-Watson Effort Aims at Optimal Cost Margins as Well as Improved Care

August 25th 2017

Investigators at Cota, a New York medical data analytics company, are taking further strides toward putting their growing knowledge of variance in care to work in the clinical setting.

FDA Approves Inotuzumab Ozogamicin for ALL

August 17th 2017

The FDA has approved inotuzumab ozogamicin for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

FDA Grants Brentuximab Vedotin Priority Review for CTCL

August 16th 2017

The FDA has granted a priority review to a supplemental biologics license application for brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma.